Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
ALNY Alnylam Pharmaceuticals, Inc. daily Stock Chart
ALNY [NASD]
Alnylam Pharmaceuticals, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-5.87 Insider Own0.20% Shs Outstand103.21M Perf Week-6.32%
Market Cap7.74B Forward P/E- EPS next Y-7.44 Insider Trans-25.07% Shs Float89.18M Perf Month-20.75%
Income-570.70M PEG- EPS next Q-2.03 Inst Own92.20% Short Float6.75% Perf Quarter-26.99%
Sales106.80M P/S72.43 EPS this Y-13.10% Inst Trans0.49% Short Ratio6.38 Perf Half Y-20.88%
Book/sh16.12 P/B4.65 EPS next Y-3.10% ROA-32.30% Target Price139.82 Perf Year-34.66%
Cash/sh14.03 P/C5.34 EPS next 5Y46.09% ROE-36.80% 52W Range72.34 - 153.99 Perf YTD-41.01%
Dividend- P/FCF- EPS past 5Y-20.80% ROI-27.80% 52W High-50.82% Beta2.65
Dividend %- Quick Ratio13.20 Sales past 5Y6.10% Gross Margin- 52W Low4.68% ATR3.54
Employees749 Current Ratio13.20 Sales Q/Q88.10% Oper. Margin- RSI (14)33.21 Volatility4.45% 4.11%
OptionableYes Debt/Eq0.02 EPS Q/Q-21.10% Profit Margin- Rel Volume0.92 Prev Close74.95
ShortableYes LT Debt/Eq0.02 EarningsNov 06 BMO Payout- Avg Volume943.84K Price75.72
Recom2.10 SMA20-9.91% SMA50-20.09% SMA200-29.03% Volume374,197 Change1.03%
Oct-01-18Initiated Cantor Fitzgerald Overweight $135
Aug-13-18Reiterated Stifel Buy $125 → $123
Aug-07-18Upgrade Stifel Hold → Buy $95 → $125
May-04-18Reiterated Stifel Hold $107 → $95
Mar-28-18Initiated Evercore ISI In-line
Mar-26-18Reiterated JMP Securities Mkt Outperform $169 → $207
Feb-16-18Reiterated B. Riley FBR, Inc. Buy $205 → $200
Jan-08-18Reiterated B. Riley FBR, Inc. Buy $220 → $205
Nov-09-17Upgrade JP Morgan Neutral → Overweight
Nov-08-17Reiterated Barclays Overweight $127 → $158
Nov-08-17Reiterated B. Riley FBR, Inc. Buy $240 → $220
Nov-03-17Reiterated Needham Buy $125 → $152
Nov-02-17Reiterated B. Riley FBR, Inc. Buy $150 → $240
Oct-30-17Initiated FBR & Co. Buy $150
Oct-02-17Upgrade Goldman Neutral → Buy
Sep-21-17Reiterated Needham Buy $85 → $125
Sep-15-17Initiated Instinet Reduce
Jun-22-17Resumed Jefferies Buy $102
May-15-17Reiterated Chardan Capital Markets Buy $95 → $110
Mar-30-17Initiated UBS Neutral $55
Oct-23-18 10:49AM  SHAREHOLDER ALERT: CBS TRCO ALNY MGTI HAS CHGG ADNT TRVN HTHT GOOG: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
Oct-22-18 08:00PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alnylam Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline ALNY ACCESSWIRE
05:22PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of LCI, PZZA, ALNY, SFIX and GOOG GlobeNewswire
04:47PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alnylam Pharmaceuticals, Inc. To Contact The Firm Business Wire
12:45PM  SHAREHOLDER NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
11:40AM  CLASS ACTION UPDATE for AMPE, ALNY and HTHT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
08:18AM  Kessler Topaz Meltzer & Check, LLP Reminds Alnylam Pharmaceuticals, Inc. Investors of Important Deadline in Securities Fraud Class Action Lawsuit GlobeNewswire
Oct-21-18 11:08AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of LCI, PVG, ALNY, MGTI, HAS and CHGG GlobeNewswire
Oct-19-18 07:08PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alnylam Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline ALNY GlobeNewswire
02:57PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 in Alnylam Pharmaceuticals, Inc. to Contact the Firm Business Wire
02:30PM  INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
11:36AM  SHAREHOLDER ALERT: LOGM SKX PVG USAT ALNY MGTI HAS HTHT GOOG: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
10:00AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alnylam Pharmaceuticals, Inc. (ALNY) and Lead Plaintiff Deadline November 26, 2018 GlobeNewswire
Oct-18-18 03:00PM  IMPORTANT SHAREHOLDER NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
11:28AM  CLASS ACTION UPDATE for PZZA, ALNY and CHGG: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
Oct-17-18 07:30PM  ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. - ALNY ACCESSWIRE
05:48PM  SHAREHOLDER ALERT: TRCO MCHP ALNY MGTI CPB CHGG ADNT TRVN SFIX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
04:15PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alnylam Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ALNY ACCESSWIRE
Oct-16-18 05:48PM  IMPORTANT SHAREHOLDER DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
04:00PM  Alnylam to Pursue Full Approval & Rolling NDA for Givosiran Zacks
11:49AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CBS, PVG, COCP and ALNY GlobeNewswire
Oct-15-18 04:15PM  IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
03:00PM  CLASS ACTION UPDATE for COCP, ABBV and ALNY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
02:35PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alnylam Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ALNY ACCESSWIRE
10:07AM  Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for Alnylam Pharmaceuticals, Inc. Investors GlobeNewswire
08:29AM  Alnylam shares drop 1.8% on new FDA approval strategy for rare disease drug MarketWatch
07:00AM  Alnylam Announces Plan to Initiate Rolling Submission of a New Drug Application and Pursue Full Approval for Givosiran Business Wire
Oct-12-18 07:25PM  IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
07:15PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alnylam Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline ALNY GlobeNewswire
01:00PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of NVRO, LOGM, USAT, ABBV and ALNY GlobeNewswire
10:00AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alnylam Pharmaceuticals, Inc. (ALNY) and Lead Plaintiff Deadline November 26, 2018 GlobeNewswire
Oct-11-18 05:45PM  IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
02:09PM  SHAREHOLDER ALERT: TRCO USAT MCHP COCP ABBV ALNY MGTI CHGG ADNT: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
Oct-10-18 11:38PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alnylam Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline (ALNY) ACCESSWIRE
02:55PM  CLASS ACTION UPDATE for ABBV, ALNY and ADNT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
01:16PM  CLASS ACTION ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Significant Losses From Investment In Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) To Contact Brower Piven Before The Lead Plaintiff Deadline GlobeNewswire
07:00AM  Alnylam Appoints Dr. Margaret Hamburg to Board of Directors Business Wire
Oct-09-18 01:33PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of USAT, MCHP, ABBV, ALNY and CPB GlobeNewswire
09:26AM  Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against Alnylam Pharmaceuticals, Inc. Business Wire
Oct-08-18 04:35PM  SHAREHOLDER ALERT: SKX PM USAT MCHP ABBV ALNY MGTI CPB CHGG ADNT: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
03:56PM  Robbins Arroyo LLP: Alnylam Pharmaceuticals, Inc. (ALNY) Sued by Shareholders in Recently Filed Class Action Business Wire
Oct-07-18 11:17AM  CLASS ACTION UPDATE for COCP, ABBV and ALNY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
Oct-06-18 03:00PM  ALNY LOSS NOTICE: Rosen Law Firm Reminds Alnylam Pharmaceuticals, Inc. Investors of Important Deadline in Class Action ALNY Business Wire
10:17AM  Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. ALNY GlobeNewswire
Oct-05-18 06:59PM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ampio, Microchip Technology, Chegg, and Alnylam and Encourages Investors to Contact the Firm GlobeNewswire
05:23PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alnylam Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline ALNY GlobeNewswire
01:10PM  IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
10:00AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alnylam Pharmaceuticals, Inc. (ALNY) and Lead Plaintiff Deadline November 26, 2018 GlobeNewswire
08:15AM  Factors of Influence in 2018, Key Indicators and Opportunity within EQT, Alnylam Pharmaceuticals, Healthcare Realty Trust, Natural Grocers by Vitamin Cottage, The Hartford Financial Services Group, and Ryder System New Research Emphasizes Economic Growth GlobeNewswire
Oct-04-18 03:18PM  Alnylam Files Clinical Trial Application for ALN-AAT02 in UK Zacks
07:00AM  Alnylam Reports Updated Positive Results from Phase 1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 Business Wire
Oct-03-18 06:05PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alnylam Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ALNY ACCESSWIRE
02:45PM  IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
02:30PM  Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Filed Against Alnylam Pharmaceuticals, Inc. - ALNY PR Newswire
11:37AM  Medicines Company to Continue Inclisiran Studies as Planned Zacks
10:50AM  Alnylam Loss Alert: Bernstein Liebhard LLP Announces That a Securities Class Action Lawsuit Has Been Filed Against Alnylam Pharmaceuticals, Inc. - ALNY GlobeNewswire
08:30AM  Kaskela Law LLC Announces Investor Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ALNY GlobeNewswire
07:00AM  Alnylam Submits Clinical Trial Authorization (CTA) Application for ALN-AAT02, an Investigational RNAi Therapeutic for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1 Liver Disease) Business Wire
02:06AM  With Hemlibra, Roche seeks to break into tight hemophilia circle Reuters
Oct-02-18 04:00PM  Alnylam Launches ONPATTRO (patisiran), the First-Ever RNAi Therapeutic, in Germany Business Wire
02:50PM  Alnylam Reports New Platform Innovations for RNAi Therapeutics at the Oligonucleotide Therapeutics Society 2018 Annual Meeting Business Wire
09:26AM  Here's Why Alynlam Pharmaceuticals is Hogging the Limelight Zacks
Oct-01-18 07:49PM  IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
05:26PM  KESSLER TOPAZ MELTZER & CHECK, LLP Announces Investor Securities Fraud Class Action Lawsuit Against ALNYLAM PHARMACEUTICALS, INC. ALNY GlobeNewswire
02:30PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alnylam Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ALNY ACCESSWIRE
Sep-28-18 08:00PM  Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Alnylam Pharmaceuticals, Inc. (ALNY) GlobeNewswire
03:00PM  CLASS ACTION UPDATE for MCHP, ABBV and ALNY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
11:34AM  IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
10:15AM  SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. - ALNY ACCESSWIRE
10:00AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Alnylam Pharmaceuticals, Inc. (ALNY) and Lead Plaintiff Deadline November 26, 2018 GlobeNewswire
07:00AM  Alnylam Class Action Lawsuit: Bernstein Liebhard LLP Announces That a Securities Class Action Lawsuit Has Been Filed Against Alnylam Pharmaceuticals, Inc. ALNY GlobeNewswire
07:00AM  Alnylam Announces Submission of New Drug Application in Japan for ONPATTRO (patisiran sodium) for Treatment of Hereditary ATTR Amyloidosis Business Wire
Sep-27-18 09:15PM  Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Alnylam Pharmaceuticals, Inc. (ALNY) and Encourages ALNY Investors to Contact the Firm GlobeNewswire
06:06PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alnylam Pharmaceuticals, Inc. To Contact The Firm PR Newswire
05:00PM  Glancy Prongay & Murray LLP Announces Investigation on Behalf of Alnylam Pharmaceuticals, Inc. Investors (ALNY) Business Wire
03:02PM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Alnylam Pharmaceuticals, Inc. (ALNY) and Lead Plaintiff Deadline - November 26, 2018 PR Newswire
02:44PM  INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Alnylam Pharmaceuticals, Inc. Investors (ALNY) Business Wire
01:10PM  Early approval of Alnylam's gene-silencing drug in question Reuters
10:37AM  ALNYLAM CLASS ACTION LAWSUIT: BERNSTEIN LIEBHARD LLP ANNOUNCES THAT A SECURITIES CLASS ACTION LAWSUIT HAS BEEN FILED AGAINST ALNYLAM PHARMACEUTICALS, INC. - ALNY PR Newswire
10:35AM  EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. ALNY Business Wire
08:42AM  Alnylam stock drops 2.6% premarket on preliminary results for rare disease therapy MarketWatch
07:45AM  Interim data on Alnylam's drug shows efficacy in late-stage trial Reuters
07:00AM  Alnylam releases promising data on rare disease drug American City Business Journals
07:00AM  Alnylam Announces Positive Topline Results from Interim Analysis of ENVISION Phase 3 Study of Givosiran in Patients with Acute Hepatic Porphyria Business Wire
Sep-26-18 10:15PM  INVESTOR ALERT: Kaskela Law LLC Announces Investor Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ALNY GlobeNewswire
07:28PM  Pomerantz Law Firm Announces the Filing of a Class Action against Alnylam Pharmaceuticals, Inc. and Certain Officers ALNY GlobeNewswire
08:00AM  Alnylam to Webcast Presentation at the 2018 Cantor Global Healthcare Conference Business Wire
Sep-24-18 07:19PM  Bragar Eagel & Squire, P.C. Reminds Investors that it is Investigating Possible Securities Fraud Violations by Certain Officers and Directors of Alnylam, Global Blood, and NiSource on Behalf of Stockholders and Encourages Investors to Contact the Firm GlobeNewswire
08:00AM  Alnylam Pharmaceuticals Receives Priority Review in Canada for Patisiran, an Investigational RNAi Therapeutic for the Treatment of Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis) with Polyneuropathy CNW Group
Sep-20-18 05:21PM  ALNYLAM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alnylam Pharmaceuticals, Inc. To Contact The Firm PR Newswire
Sep-18-18 07:30PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY ACCESSWIRE
Sep-14-18 05:23PM  ALNYLAM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alnylam Pharmaceuticals, Inc. To Contact The Firm GlobeNewswire
07:30AM  Alnylam Investigation: Bernstein Liebhard LLP Announces Investigation of Alnylam Pharmaceuticals, Inc. - ALNY GlobeNewswire
06:00AM  Alnylam Announces Publication in Circulation of Exploratory Cardiac Endpoint Data from APOLLO Phase 3 Study of Patisiran Business Wire
Sep-13-18 03:38PM  Alnylam Investigation: Bernstein Liebhard LLP Announces Investigation Of Alnylam Pharmaceuticals, Inc. - ALNY PR Newswire
02:42PM  Bragar Eagel & Squire, P.C. is Investigating Alnylam Pharmaceuticals, Inc. on Behalf of Stockholders and Encourages Investors to Contact the Firm GlobeNewswire
Sep-12-18 05:42PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY PR Newswire -5.58%
02:14PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alnylam Pharmaceuticals, Inc. (ALNY) PR Newswire
Sep-07-18 02:32PM  Here's Why Dicerna Pharmaceuticals, Inc. Is on a Roller Coaster; Down 18% Yesterday, Up 17% Today Motley Fool
Sep-04-18 05:36AM  What you missed on your summer vacation in Mass. biotech news American City Business Journals
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia. Its clinical programs also include ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR, which is in the Phase I clinical trial for the treatment of various forms of ATTR amyloidosis; Lumasiran (ALN-GO1) that is in Phase I/II clinical trial for the treatment of primary hyperoxaluria type 1; and Cemdisiran (ALN-CC5), which is in the Phase II clinical trial for the treatment of complement-mediated diseases. The company has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc; and Regeneron Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Greenstreet YvonneEVP, Chief Operating OfficerAug 30Sale120.002,500300,0001,916Sep 04 04:15 PM
MARAGANORE JOHNChief Executive OfficerJul 25Option Exercise21.3550,0001,067,500201,297Jul 27 04:07 PM
MARAGANORE JOHNChief Executive OfficerJul 25Sale105.3950,0005,269,457151,297Jul 27 04:07 PM
KEATING LAURIESVP, GC & SecretaryJun 20Option Exercise42.221,56365,99016,063Jun 22 04:20 PM
KEATING LAURIESVP, GC & SecretaryJun 20Sale105.041,563164,17814,500Jun 22 04:20 PM
CLARKE JOHN KDirectorMay 31Option Exercise27.2815,000409,20023,891Jun 04 04:25 PM
CLARKE JOHN KDirectorMay 31Sale100.3115,0001,504,6788,891Jun 04 04:25 PM
Greenstreet YvonneEVP, Chief Operating OfficerMar 26Option Exercise42.227,221304,8717,221Mar 28 04:39 PM
Greenstreet YvonneEVP, Chief Operating OfficerMar 26Sale136.547,221985,9580Mar 28 04:39 PM
KEATING LAURIESVP, GC & SecretaryMar 20Option Exercise42.221,56265,94816,062Mar 22 06:18 PM
KEATING LAURIESVP, GC & SecretaryMar 20Sale149.831,562234,03314,500Mar 22 06:18 PM
Vaishnaw AkshayPresident, R&DMar 14Option Exercise17.0388,5541,507,84299,769Mar 16 05:05 PM
Greene Barry EPresidentMar 14Sale143.1038,4605,503,73661,968Mar 16 05:05 PM
Vaishnaw AkshayPresident, R&DMar 14Sale143.1088,55412,672,12611,215Mar 16 05:05 PM
SCHIMMEL PAULDirectorMar 13Option Exercise49.2427,8231,369,92727,823Mar 14 07:39 PM
SHARP PHILIP ADirectorMar 13Option Exercise21.3515,000320,250155,795Mar 14 07:39 PM
KEATING LAURIESVP, GC & SecretaryMar 13Option Exercise77.4010,000774,00024,500Mar 14 07:40 PM
Ausiello Dennis ADirectorMar 13Option Exercise59.8217,1171,023,94217,117Mar 14 07:40 PM
KEATING LAURIESVP, GC & SecretaryMar 13Sale150.0010,0001,500,00014,500Mar 14 07:40 PM
SCHIMMEL PAULDirectorMar 13Sale150.0027,8234,173,4500Mar 14 07:39 PM
Ausiello Dennis ADirectorMar 13Sale150.0017,1172,567,5500Mar 14 07:40 PM
SHARP PHILIP ADirectorMar 13Sale149.0015,0002,235,000140,795Mar 14 07:39 PM
KEATING LAURIESVP, GC & SecretaryMar 12Option Exercise77.4010,000774,00024,500Mar 14 07:40 PM
KEATING LAURIESVP, GC & SecretaryMar 12Sale140.0010,0001,400,00014,500Mar 14 07:40 PM
SHARP PHILIP ADirectorMar 09Option Exercise27.2815,000409,200155,795Mar 13 05:22 PM
SHARP PHILIP ADirectorMar 09Sale129.0015,0001,935,000140,795Mar 13 05:22 PM
Mason MichaelVP, Finance and TreasurerJan 04Option Exercise88.2631,7812,804,91136,745Jan 08 05:02 PM
Mason MichaelVP, Finance and TreasurerJan 04Sale131.5936,7454,835,1710Jan 08 05:02 PM
Mason MichaelVP, Finance and TreasurerDec 30Option Exercise0.008,50208,502Jan 03 05:26 PM
KEATING LAURIESVP, GC & SecretaryDec 29Option Exercise77.403,000232,20014,500Jan 03 05:13 PM
KEATING LAURIESVP, GC & SecretaryDec 20Option Exercise42.226,249263,83317,749Dec 21 05:00 PM
KEATING LAURIESVP, GC & SecretaryDec 20Sale121.206,249757,39811,500Dec 21 05:00 PM
MARAGANORE JOHNChief Executive OfficerDec 19Option Exercise63.001,58799,981151,297Dec 21 04:36 PM
KEATING LAURIESVP, GC and SecretaryDec 01Option Exercise77.4030,0002,322,00041,500Dec 05 05:47 PM
KEATING LAURIESVP, GC and SecretaryDec 01Sale135.8930,0004,076,82311,500Dec 05 05:47 PM
MARAGANORE JOHNChief Executive OfficerNov 22Option Exercise31.3973,4152,304,497223,125Nov 24 06:55 PM
MARAGANORE JOHNChief Executive OfficerNov 22Sale130.9073,4159,609,736149,710Nov 24 06:55 PM
MARAGANORE JOHNChief Executive OfficerNov 15Option Exercise31.3974,0002,322,860223,710Nov 17 05:35 PM
MARAGANORE JOHNChief Executive OfficerNov 15Sale126.8674,0009,387,951149,710Nov 17 05:35 PM
Ausiello Dennis ADirectorNov 02Option Exercise30.0920,000601,80020,000Nov 03 08:14 PM
Ausiello Dennis ADirectorNov 02Sale130.0020,0002,600,0000Nov 03 08:14 PM
Vaishnaw AkshayEVP, R&DOct 30Option Exercise21.3533,666718,76945,201Nov 01 05:33 PM
Vaishnaw AkshayEVP, R&DOct 30Sale121.4633,6664,088,96711,535Nov 01 05:33 PM
open in yahoo | open in reuters | open in google